{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T16:19:53Z","timestamp":1700237993650},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2003,3,1]],"date-time":"2003-03-01T00:00:00Z","timestamp":1046476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2003,3]]},"DOI":"10.1016\/s0145-2126(02)00089-9","type":"journal-article","created":{"date-parts":[[2003,1,21]],"date-time":"2003-01-21T19:04:26Z","timestamp":1043175866000},"page":"205-214","source":"Crossref","is-referenced-by-count":16,"title":["Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors"],"prefix":"10.1016","volume":"27","author":[{"given":"Emmanuelle","family":"Tavernier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quoc-Hung","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Elhamri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0145-2126(02)00089-9_BIB1","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2141.1992.tb08203.x","article-title":"A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukemia","volume":"81","author":"Schiller","year":"1992","journal-title":"Br. J. Haematol."},{"key":"10.1016\/S0145-2126(02)00089-9_BIB2","first-page":"217","article-title":"For the Cancer and Leukemia Group B. Intensive postremission chemotherapy in adults with acute myeloid leukemia","volume":"332","author":"Mayer","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/S0145-2126(02)00089-9_BIB3","first-page":"1025","article-title":"Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia","volume":"9","author":"Te Boekhorst","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/S0145-2126(02)00089-9_BIB4","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/0014-2964(74)90079-6","article-title":"The experimental antitumor properties of three congeners of the acridly methanesulphonanilide (AMSA) series","volume":"10","author":"Cain","year":"1974","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/S0145-2126(02)00089-9_BIB5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7326\/0003-4819-93-1-17","article-title":"4\u2032-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia","volume":"93","author":"Legha","year":"1980","journal-title":"Ann. Int. Med."},{"key":"10.1016\/S0145-2126(02)00089-9_BIB6","first-page":"3304","article-title":"Phase I and II trial of 4\u2032-(9-acridinylamino) methanesulfon-m-anisidide in patients with acute leukemia","volume":"40","author":"Arlin","year":"1980","journal-title":"Cancer Res."},{"key":"10.1016\/S0145-2126(02)00089-9_BIB7","first-page":"203","article-title":"m-AMSA: an exciting new drug in the National Cancer Institute Drug Development Program","volume":"3","author":"Weiss","year":"1980","journal-title":"Cancer Clin. Trials"},{"key":"10.1016\/S0145-2126(02)00089-9_BIB8","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1200\/JCO.1984.2.6.545","article-title":"High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute non-lymphocytic leukemia","volume":"2","author":"Hines","year":"1984","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0145-2126(02)00089-9_BIB9","first-page":"317","article-title":"Treatment of acute leukemia in relapse with 4\u2032-(9 acridinylamino)-methansulfon-m-anisidide (AMSA) in combination with cytosine and thioguanine","volume":"4","author":"Arlin","year":"1981","journal-title":"Cancer Clin. Trials."},{"key":"10.1016\/S0145-2126(02)00089-9_BIB10","unstructured":"Vogler WR, Stein R, Velez-Garcia E, et al. New approaches in the treatment of acute myeloblastic leukemia: results of recent Southeastern Study Group trials. In: Gale RP, editor. Acute myelogenous leukemia: progress and controversies. New York: Wiley, 1990. p. 303\u201312."},{"key":"10.1016\/S0145-2126(02)00089-9_BIB11","first-page":"115","article-title":"Comparative trial of cytarabine and thioguanine in combination with amsacrine and daunorubicin in patients with untreated acute non-lymphocytic leukemia: results of the L-16M protocol","volume":"3","author":"Berman","year":"1989","journal-title":"Leukemia"},{"key":"10.1016\/S0145-2126(02)00089-9_BIB12","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.1994.12.2.262","article-title":"Prospective genetically randomized comparison between intensive postinduction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia","volume":"12","author":"Archimbaud","year":"1994","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 2","key":"10.1016\/S0145-2126(02)00089-9_BIB13","first-page":"133","article-title":"For the AML Study Group. Preliminary results of LAM 90 trial on adult acute myelogenous leukemia: Comparison of standard induction chemotherapy versus double or sequential induction chemotherapy","volume":"93","author":"Castaigne","year":"1996","journal-title":"Br. J. Haematol."},{"key":"10.1016\/S0145-2126(02)00089-9_BIB14","first-page":"626","article-title":"Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French\u2013American\u2013British Cooperative Group","volume":"103","author":"Bennett","year":"1985","journal-title":"Ann. Int. Med."},{"key":"10.1016\/S0145-2126(02)00089-9_BIB15","doi-asserted-by":"crossref","unstructured":"ISCN (International System for Human Cytogenetic Nomenclature). Guidelines for cancer cytogenetics. In: Mitelman F, editor. Supplement to an International System for Human Cytogenetic Nomenclature. Basel: Karger, 1991. p. 1\u201353.","DOI":"10.1159\/000132882"},{"key":"10.1016\/S0145-2126(02)00089-9_BIB16","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood.V32.4.507.507","article-title":"Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults","volume":"32","author":"Ellison","year":"1968","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(02)00089-9_BIB17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/mpo.2950040311","article-title":"Failure of remission induction in acute myelocytic leukemia","volume":"4","author":"Preisler","year":"1978","journal-title":"Med. Pediatr. Oncol."},{"key":"10.1016\/S0145-2126(02)00089-9_BIB18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariate prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat. Med."},{"key":"10.1016\/S0145-2126(02)00089-9_BIB19","first-page":"379","article-title":"Phase II-study for treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine","volume":"13","author":"Jehn","year":"1993","journal-title":"Anticancer Res."},{"issue":"Suppl. 1","key":"10.1016\/S0145-2126(02)00089-9_BIB20","first-page":"S24","article-title":"A randomized phase II study on the effects of 5-aza-2\u2032-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893)","volume":"11","author":"Willemze","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/S0145-2126(02)00089-9_BIB21","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/00000421-198308000-00018","article-title":"4\u2032-(9-acridinylamino)methane-sulfon-m-anisidide (m-AMSA) and 5-azacytidine (AZA) in the treatment of relapsed adult acute leukemia","volume":"6","author":"Kahn","year":"1983","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/S0145-2126(02)00089-9_BIB22","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/mpo.2950130414","article-title":"Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia","volume":"13","author":"Letendre","year":"1985","journal-title":"Med. Pediatr. Oncol."},{"key":"10.1016\/S0145-2126(02)00089-9_BIB23","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.1987.5.5.710","article-title":"A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia","volume":"5","author":"Keating","year":"1987","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0145-2126(02)00089-9_BIB24","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/1097-0142(19910915)68:6<1198::AID-CNCR2820680603>3.0.CO;2-E","article-title":"Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia","volume":"68","author":"Arlin","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/S0145-2126(02)00089-9_BIB25","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.1984.2.2.102","article-title":"Prediction of complete remission in patients with refractory acute leukemia treated with AMSA","volume":"12","author":"Estey","year":"1984","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0145-2126(02)00089-9_BIB26","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1182\/blood.V73.1.263.263","article-title":"Prognostic impact of cytogenetic abnormalities in patients with de novo acute non-lymphocytic leukemia","volume":"73","author":"Schiffer","year":"1989","journal-title":"Blood"},{"key":"10.1016\/S0145-2126(02)00089-9_BIB27","first-page":"403","article-title":"Cytogenetic pattern in acute myelogenous leukemia: a major reproductible determinant of outcome","volume":"2","author":"Keating","year":"1988","journal-title":"Leukemia"},{"key":"10.1016\/S0145-2126(02)00089-9_BIB28","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","article-title":"Goldstone A on behalf of the Medical Research Council Adult and Children\u2019s Leukaemia Working Parties. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial","volume":"92","author":"Grimwade","year":"1998","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212602000899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212602000899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,7]],"date-time":"2020-03-07T02:08:07Z","timestamp":1583546887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212602000899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,3]]}},"alternative-id":["S0145212602000899"],"URL":"https:\/\/doi.org\/10.1016\/s0145-2126(02)00089-9","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2003,3]]}}}